SEC Form 4 · accession 0001723884-26-000005
Faeth Therapeutics, Inc. · FTH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Karen H Vousden
Director
Period of report
Sep 11, 2026
Accepted (ET)
Sep 15, 2026 · 4:58 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001829802
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $37.44 | Sep 11, 2026 | A | 25,000 | A | — | Sep 10, 2036 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1The shares subject to the option vest and become exercisable in 36 equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, or September 11, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.